Repligen Corp. Stock
Price
Target price
€104.55
€104.55
0.330%
0.35
0.330%
€171.79
29.08.25 / Tradegate
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Repligen Corp. Stock
Repligen Corp. gained 0.330% compared to yesterday.
We see a rather positive sentiment for Repligen Corp. with 14 Buy predictions and 1 Sell predictions.
As a result the target price of 171 € shows a very positive potential of 63.56% compared to the current price of 104.55 € for Repligen Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Repligen Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Repligen Corp. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | 0.330% | -1.877% | -3.685% | -19.885% | -25.295% | -52.671% | -17.221% |
| Opko Health Inc. | -1.200% | 1.813% | 3.415% | -16.501% | -16.717% | -49.374% | -58.231% |
| Amicus Therapeutics Inc. | 0.780% | 0.000% | 23.810% | -34.673% | -28.962% | -41.683% | -45.833% |
| Hutchison China Meditech Ltd | 1.690% | -6.977% | -23.567% | -21.053% | -6.977% | 0.000% | -55.056% |
Comments
Repligen Corporation (NASDAQ: RGEN) had its price target raised by analysts at Royal Bank Of Canada from $193.00 to $204.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) had its price target lowered by analysts at Wells Fargo & Company from $180.00 to $175.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) is now covered by analysts at Stephens. They set an "overweight" rating and a $160.00 price target on the stock.
Show more
Ratings data for RGEN provided by MarketBeat